Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Io Biotech, Inc. (IOBT)
:IOBT
Holding IOBT?
Track your performance easily
IOBT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.66 - $1.89
Previous CloseN/A
Volume57.25K
Average Volume (3M)235.66K
Market Cap
$55.12M
Enterprise Value-$8.99M
Total Cash (Recent Filing)$7.85M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Mar 27, 2025EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.37
Shares Outstanding65,880,910
10 Day Avg. Volume132,299
30 Day Avg. Volume235,662
Standard Deviation0.23
R-Squared0.00281
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.10
Forecast
1Y Price Target
$9.00Price Target Upside971.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
IO Biotech News
PremiumCompany Announcements
IO Biotech Secures €57.5 Million EIB Loan Facility
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressEnrollment in the Ph2 adjuvant/neoadjuvant basket trial in melanoma and HNSCC is progressing ahead of expectations.
Efficacy Of TreatmentThe safety profile of IO102-IO103 combined with pembrolizumab was manageable with low rates of severe adverse events, and the treatment demonstrated responses in both HPV positive and negative patients, indicating potential broad efficacy.
Financial PerformanceEnded 3Q24 with $80.2M in cash, which is expected to support operations into 4Q25.
Bears Say
Clinical Trial ResultsThe interim results from the Phase 3 study did not meet statistical significance, and there is uncertainty regarding the numerical benefit in the treatment arm as the ORR numbers were not disclosed.
Efficacy ConcernsThe updated ORR appears to be only marginally additive to pembro alone of less than 10%, raising doubts about the potential survival benefit.
Safety ConcernsThe safety profile showed Grade 3-4 treatment-related adverse events in 24% of patients, which is slightly higher than some comparable studies.
---
Ownership Overview
28.12% Insiders
0.83% Mutual Funds
26.23% Other Institutional Investors
44.82% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IOBT FAQ
What was Io Biotech, Inc.’s price range in the past 12 months?
Io Biotech, Inc. lowest stock price was $0.66 and its highest was $1.89 in the past 12 months.
What is Io Biotech, Inc.’s market cap?
Io Biotech, Inc.’s market cap is $55.12M.
When is Io Biotech, Inc.’s upcoming earnings report date?
Io Biotech, Inc.’s upcoming earnings report date is Mar 27, 2025 which is in 64 days.
How were Io Biotech, Inc.’s earnings last quarter?
Io Biotech, Inc. released its earnings results on Nov 12, 2024. The company reported -$0.36 earnings per share for the quarter, missing the consensus estimate of -$0.288 by -$0.072.
Is Io Biotech, Inc. overvalued?
According to Wall Street analysts Io Biotech, Inc.’s price is currently Undervalued.
Does Io Biotech, Inc. pay dividends?
Io Biotech, Inc. does not currently pay dividends.
What is Io Biotech, Inc.’s EPS estimate?
Io Biotech, Inc.’s EPS estimate is -0.39.
How many shares outstanding does Io Biotech, Inc. have?
Io Biotech, Inc. has 65,880,910 shares outstanding.
What happened to Io Biotech, Inc.’s price movement after its last earnings report?
Io Biotech, Inc. reported an EPS of -$0.36 in its last earnings report, missing expectations of -$0.288. Following the earnings report the stock price went down -11.429%.
Which hedge fund is a major shareholder of Io Biotech, Inc.?
Among the largest hedge funds holding Io Biotech, Inc.’s share is RA Capital Management. It holds Io Biotech, Inc.’s shares valued at 0.
---
IO Biotech Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.00 (971.43% Upside)
$9.00 (971.43% Upside)
Blogger Sentiment
Bullish
IOBT Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $54.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.1%
Last 30 Days ▼ 6.8%
Last 30 Days ▼ 6.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.55%
12-Months-Change
Fundamentals
Return on Equity
-78.50%
Trailing 12-Months
Asset Growth
-47.87%
Trailing 12-Months
Company Description
Io Biotech, Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
---
IOBT Stock 12 Month Forecast
Average Price Target
$9.00
▲(971.43% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Kala Pharmaceuticals
―
TG Therapeutics
―
Karyopharm Therapeutics
―
Best Analysts Covering IOBT
1 Year
1 Year Success Rate
1/8 ratings generated profit
1 Year Average Return
-30.21%
assigned a buy rating 2 months ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -30.21% per trade.
---